Comparing Dasatinib vs Methotrexate
Dasatinib | Methotrexate |
|
---|
Dasatinib | Methotrexate |
|
|||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Prescribed for Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Leukemia. Dasatinib may also be used for purposes not listed in this medication guide. |
Prescription only
Methotrexate may be considered for the treatment of psoriasis, rheumatoid arthritis, polyarticular juvenile idiopathic arthritis (pJIA), mycosis fungoides, and certain cancers, such as ALL or... View more |
Related suggestions Acute Lymphoblastic Leukemia
|
|||||||||||||||
More about Dasatinib | More about Methotrexate | ||||||||||||||||
Ratings & Reviews | |||||||||||||||||
Dasatinib has an average rating of 7.7 out of 10 from a total of 27 ratings on Drugs.com. 70% of reviewers reported a positive effect, while 15% reported a negative effect. |
Methotrexate has an average rating of 6.5 out of 10 from a total of 339 ratings on Drugs.com. 53% of reviewers reported a positive effect, while 24% reported a negative effect. |
||||||||||||||||
Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||||||||||
View all Dasatinib side effects |
View all Methotrexate side effects |
||||||||||||||||
Drug Class | |||||||||||||||||
Generic Availability | |||||||||||||||||
Lower cost generic |
Lower cost generic |
||||||||||||||||
Pricing and Coupons * Prices are without insurance | |||||||||||||||||
View all Dasatinib prices |
View all Methotrexate prices |
||||||||||||||||
Dosage Forms | |||||||||||||||||
|
|
||||||||||||||||
Brand Names | |||||||||||||||||
Phyrago, Sprycel | Jylamvo, Methotrexate LPF Sodium, Otrexup, Rasuvo, Trexall, Xatmep | ||||||||||||||||
Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||||||||||
5 hours |
15 hours |
||||||||||||||||
CSA Schedule 1 View glossary of CSA terms | |||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
Pregnancy Category | |||||||||||||||||
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category X
Not for use in pregnancy
See the full pregnancy warnings document. |
||||||||||||||||
Drug Interactions | |||||||||||||||||
A total of 817 drugs are known to interact with Dasatinib:
|
A total of 731 drugs are known to interact with Methotrexate:
|
||||||||||||||||
Alcohol/Food/Lifestyle Interactions | |||||||||||||||||
|
|||||||||||||||||
Disease Interactions | |||||||||||||||||
First Approval Date | |||||||||||||||||
June 28, 2006 |
December 07, 1953 |
||||||||||||||||
WADA Class View classifications | |||||||||||||||||
N/A |
N/A |
||||||||||||||||
More Information | |||||||||||||||||
Patient Resources | |||||||||||||||||
Professional Resources | |||||||||||||||||
Related Treatment Guide | |||||||||||||||||
|
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Hydrea
Hydrea is used for chronic myelogenous leukemia, head and neck cancer
Gleevec
Gleevec is targeted cancer therapy for specific types of leukemia (blood cancer), bone marrow ...
Dupixent
Dupixent is used to treat eczema, eosinophilic or oral-corticosteroid-dependent asthma, chronic ...
Sprycel
Sprycel is used to treat chronic myeloid leukemia and acute lymphoblastic leukemia. Learn about ...
Tasigna
Tasigna (nilotinib) is used to treat Philadelphia chromosome positive chronic myeloid leukemia ...
Cytoxan
Cytoxan is used for acute lymphocytic leukemia, acute nonlymphocytic leukemia, breast cancer ...
Scemblix
Scemblix (asciminib) is an oral kinase inhibitor that may be used to treat adults with a type of ...
Bosulif
Bosulif is a kinase inhibitor that may be used to treat adults and some children aged 1 year and ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.